目的 探讨地塞米松联合屈螺酮炔雌醇治疗多囊卵巢综合征的临床疗效。方法 选取2013年6-2015年7月连云港市东方医院收治的多囊卵巢综合征患者80例，随机分为对照组和治疗组，每组各40例。对照组患者在月经周期第5天起口服屈螺酮炔雌醇片，1片/次，1次/d，连续服用21 d为1个周期，停药后待患者出现撤退性出血的第5天进行下个周期的治疗。治疗组在对照组治疗基础上在患者月经周期第1天起口服醋酸地塞米松片，1片/次，1次/d，直到患者排卵后停止服用。两组均连续治疗3个周期。对比两组患者治疗前后激素水平、胰岛素抵抗、空腹胰岛素水平等。结果 治疗后，两组患者的促黄体生成素（LH）、睾酮（T）水平均显著下降，同组治疗前后差异有统计学意义（P<0.05）；治疗后，治疗组LH、T水平低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者的空腹胰岛素（FIN）、计算胰岛素抵抗指数（HOMA-IR）均显著降低，同组治疗前后差异有统计学意义（P<0.05）；治疗后，治疗组FIN、HOMA-IR低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，对照组和治疗组的排卵率分别为37.5%、65.0%，妊娠率分别为25.0%、52.5%，两组比较差异具有统计学意义（P<0.05）。结论 地塞米松联合屈螺酮炔雌醇治疗多囊卵巢综合征具有较好的临床疗效，能明显改善患者胰岛素抵抗和性激素水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of dexamethasone combined with drospirenone and ethinylestradiol in treatment of polycystic ovary syndrome. Methods Patients (80 cases) with polycystic ovary syndrome in Oriental Hospital and Foreign Related Hospital of Lianyungang from June 2013 to July 2015 were randomly divided into control and treatment groups, and each group had 40 cases. The patients in the control group were po administered with Drospirenone and Ethinylestradiol Tablets from day 5 of the menstrual cycle, 1 tablet/time, once daily, 21 d was as one cycle. The next cycle of treatment was proceeded on day 5 of withdrawal bleeding. The patients in the treatment group were po administered with Dexamethasone Acetate Tablets on the basis of the control group from day 1 of menstrual cycle, 1 tablet/time, once daily. They stopped taking until ovulation. The patients in two groups were treated for three cycles. The levels of hormone, insulin resistance, and fasting insulin in two groups before and after treatment were compared. Results After treatment, the levels of LH and T in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the levels of LH and T in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of FIN and HOMA-IR in treatment group were significantly decreased, and the difference was significant in the same group (P<0.05). After treatment, the levels of FIN and HOMA-IR in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05).The ovulation rates in the control and treatment groups were 37.5% and 65.0%, and the pregnancy rates in two groups were 25.0% and 52.5%, respectively, and there were differences between two groups (P<0.05). Conclusion Dexamethasone combined with drospirenone and ethinylestradiol has clinical curative effect in treatment of polycystic ovary syndrome, and can significantly improve insulin resistance and sex hormone levels, which has a certain clinical application value.